Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OpcemISA: ISA101b + Cemiplimab in HPV16+ OPC
NCT03669718Phase 2Active, not recruiting
- Sponsor
- ISA Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Sep 2024
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 13
01
Overview
A Phase 2 trial of SLP-HPV-01 in oropharyngeal cancer, sponsored by ISA Pharmaceuticals. Started Nov 2018; status: active, not recruiting.
02
Drugs
SLP-HPV-01
03
Conditions
oropharyngeal cancer
Beyond the preview
Go deeper on NCT03669718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03669718.